Results 181 to 190 of about 343,983 (293)

International Policy Approaches for Higher THC Cannabis Products: Are They Applicable to the Australian Medicinal Cannabis Framework? [PDF]

Drug Alcohol Rev
Graham M, Assefa D, Carter A, Nielsen S.
europepmc   +1 more source

Effectiveness of tobacco cessation interventions in adolescents: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Globally, around 11% of adolescents aged 13–15 years use tobacco products, and over one‐third of users are estimated to be tobacco dependent. Interventions to support adolescents to quit smoking are recommended to mitigate adverse health effects.
Courtney Barnes, Heidi Turon, Sam McCrabb, Alix Hall, Cassandra Lane, Kate Bartlem, Lucy Couper, Madeleine Fee, Stephanie Mantach, Kate Mellors, Caitlin Bialek, Kate O'Brien, Luke Wolfenden   +12 more
wiley   +1 more source

Health Behaviors in Adolescent and Young Adult (AYA) Childhood Cancer Survivors: Prevalence, Determinants, and Comparison With Population Controls. [PDF]

Cancer Med
de Beijer IAE, van den Oever SR, Lawal OA, Adham H, Ashofor T, Button A, Duong J, Taylor R, Giles J, Pluijm SMF, Reynolds K, Schulte F.   +11 more
europepmc   +1 more source

Variation in 90‐day substance use disorder‐related acute care events across United States opioid treatment programs: A Medicaid claims analysis

Addiction, EarlyView.
Abstract Background and aims Creating and tracking quality measures has improved outcomes in many areas of healthcare; however, quality measures specific to opioid treatment programs (OTPs) have not yet been developed. Based on the success seen in other fields, introducing quality measures in OTPs should help enhance positive outcomes and decrease ...
Barrett Wallace Montgomery, Tami L. Mark, Thanh Lu, William N. Dowd, Dylan DeLisle, Kathryn N. Burke, Daniel H. Barch, Gary A. Zarkin   +7 more
wiley   +1 more source

Heroin overdose risk profiles following long‐term heroin dependence: Findings from the 18‐ to 20‐year follow‐up of the Australian treatment outcome study

Addiction, EarlyView.
Abstract Aims To identify heroin overdose and polydrug risk profiles of Australian adults with long‐term heroin dependence and assess if psychosocial, treatment, physical and mental health‐related covariates were associated with class membership. Design The 18–20‐year follow‐up of the Australian Treatment Outcome Study (ATOS). Setting Sydney, New South
Jessy S. Lim, Christina Marel, Tim Slade, Jack Wilson, Maree Teesson, Paul S. Haber, Katherine L. Mills   +6 more
wiley   +1 more source

Cannabis-Based Medicinal Products for Endometriosis: A 2-Year Prospective Analysis From the UK Medical Cannabis Registry. [PDF]

Aust N Z J Obstet Gynaecol
Ahmed T, Erridge S, Clarke E, McLachlan K, Coomber R, Barnes S, Medniuk AD, Guru R, Holden W, Sajad M, Searle R, Usmani A, Rucker JJ, Platt M, Sodergren MH.   +14 more
europepmc   +1 more source

Clinical features of mental imagery in substance use disorders: A mixed‐methods analysis

Addiction, EarlyView.
Abstract Aims To characterise the frequency, features and content of craving‐related mental imagery among people seeking treatment for substance use disorders (SUDs); examine within‐session change in self‐reported craving following imagery elicitation; and explore perceived links with autobiographical memory, behavioural, cognitive and emotional ...
Gemma Scott, Tim Meynen, Francesca Small, Luke Mitcheson, Elizabeth Appiah‐Kusi, William Barber, Colette Hirsch, John Marsden   +7 more
wiley   +1 more source

Beyond symptom change: a qualitative descriptive study of reported quality of life experiences among adults prescribed medicinal cannabis for anxiety disorders. [PDF]

Int J Clin Pharm
Roberts L, Cumming C, Budgeon CA, Preen DB, Lee K.   +4 more
europepmc   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Beyond Pharmacokinetics: Gaps for Rational Use of Medicinal Cannabis. [PDF]

J Clin Pharmacol
Lu S, Liu X, Truong L, Liu Z, Guo F, Martin J, Zhu X.   +6 more
europepmc   +1 more source